...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption

Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption

https://www.resverlogix.com/investors/news.html?article=670

CALGARY, Alberta, July 28, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of certain continuous disclosure documents for a period of up to 45 days.

The Company intends to rely on the exemptive relief to extend the date of filing of its annual financial statements for the year ended April 30, 2020 and related management's discussion and analysis pursuant to National Instrument 51-102 (collectively, the "Annual Filings").

Resverlogix expects to rely on the exemption to file the Annual Filings on or before September 11, 2020, and notes that management and other insiders are subject to a trading black-out policy that reflects the principles in section 9 of National Policy 11-207.

Resverlogix confirms there have been no undisclosed material business developments since the filing on March 13, 2020 of the Company’s condensed interim consolidated financial statements and associated management's discussion and analysis for the nine-month period ended January 31, 2020 that have not been otherwise disclosed by Resverlogix by way of news release.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.

BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on:

For further information please contact:

Investor Relations
Email: [email protected]
Phone: 403-254-9252
Or visit our website: www.resverlogix.com

Share
New Message
Please login to post a reply